This is the best summary I could come up with:
"We are experiencing a temporary supply disruption with the Ozempic 1 mg (injection) pen due to the combination of overall global supply constraints coupled with increased demand," said Novo Nordisk spokesperson Kate Hanna in an emailed statement.
On its website, Health Canada said "intermittent shortages" are expected from late August to early October.
The lower-dose pens "may be an option for some patients to mitigate the impacts" of the supply disruption, Health Canada's web page said.
Health Canada and Novo Nordisk are "closely monitoring" the supply of Rybelsus, which is the pill form of semaglutide, the active ingredient in Ozempic, the web page said.
But some doctors and ethics experts have criticized Novo Nordisk for aggressively marketing both Ozempic and Rybelsus in Canada in recent months, citing concerns that people will seek prescriptions for cosmetic weight loss.
Another semaglutide drug manufactured by Novo Nordisk, Wegovy, has been approved by Health Canada for the treatment of obesity, but it is not yet available in this country.
The original article contains 355 words, the summary contains 165 words. Saved 54%. I'm a bot and I'm open source!